274 related articles for article (PubMed ID: 15718848)
1. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
[TBL] [Abstract][Full Text] [Related]
2. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
3. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
5. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
7. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
8. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
9. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
10. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
16. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
Boschi A; Tinelli C; Ortolani P; Arlotti M
J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
[TBL] [Abstract][Full Text] [Related]
17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
18. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
[TBL] [Abstract][Full Text] [Related]
19. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
20. [CD4+ guided interruption HAART in HIV patients].
Antolini D; Lanzafame M; Lattuada E; Vento S; Concia E
Recenti Prog Med; 2007 Oct; 98(10):501-5. PubMed ID: 17970175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]